Pharmigene, Inc. (TPEX:7595)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
7.88
+0.15 (1.94%)
Jul 21, 2026, 1:53 PM CST
Market Cap390.09M -31.9%
Revenue (ttm)199.89M +71.5%
Net Income-73.00M
EPS-1.45
Shares Out 50.47M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume174,061
Open7.75
Previous Close7.73
Day's Range6.95 - 7.88
52-Week Range5.90 - 14.10
Beta0.05
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variatio... [Read more]

Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7595
Full Company Profile

Financial Performance

In 2025, Pharmigene's revenue was 199.89 million, an increase of 71.53% compared to the previous year's 116.53 million. Losses were -73.00 million, -11.91% less than in 2024.

Financial Statements